{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:10:40Z","timestamp":1793049040530,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Among persons with type 2 diabetes mellitus (T2DM) hypomagnesaemia has been reported in 14\u201348% of patients. This may be of significance given the emerging associations of hypomagnesaemia with glucometabolic disturbances and possibly even complications. We assessed the prevalence of hypomagnesaemia and its determinants, in a well-defined cohort of persons with T2DM treated in primary care.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Observational cohort study among persons with T2DM treated in primary care in the Northeast of the Netherlands. Magnesium was measured using a colorimetric endpoint assay (Roche). Hypomagnesaemia was defined as a serum magnesium level &lt;0.70\u2009mmol\/L. Pearson correlations were performed to correlate variables with serum magnesium. Next, a stepwise backward regression model was made.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data of 929 persons (55% male) with a mean age of 65 (\u00b1\u200910) years, diabetes duration 6.5 [3.0\u201310.1] years, and HbA1c concentration 6.7 (\u00b1\u20090.7)% (50 (\u00b1\u20099) mmol\/mol) were analysed. Serum magnesium was 0.79 (\u00b1\u20090.08)\u2009mmol\/L. The percentage of persons with magnesium deficiency was 9.6%. Age, diabetes duration, BMI, HbA1c, use of metformin, sulfonylurea derivatives, and DPP4 inhibitors were negatively associated with magnesium concentrations. In contrast, LDL cholesterol and serum creatinine were positively associated serum magnesium.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hypomagnesaemia was present in 9.6% of T2DM patients treated in primary care. This percentage is remarkably lower than reported previously, possibly due to the unselected nature of our population. Concerning T2DM-related factors, only BMI, HbA1c and the use of metformin, sulfonylurea derivatives and DPP4 inhibitors correlated negatively with magnesium concentrations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-019-02116-3","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T12:21:07Z","timestamp":1572006067000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hypomagnesaemia and its determinants in a contemporary primary care cohort of persons with type 2 diabetes"],"prefix":"10.1007","volume":"67","author":[{"given":"Femke","family":"Waanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel J.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"van Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk J. G.","family":"Bilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-6551","authenticated-orcid":false,"given":"Peter R.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"2116_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2337\/db15-1028","volume":"65","author":"LMM Gommers","year":"2016","unstructured":"L.M.M. Gommers, J.G.J. Hoenderop, R.J.M. Bindels, J.H.F. de Baaij, Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes 65, 3\u201313 (2016). \nhttps:\/\/doi.org\/10.2337\/db15-1028","journal-title":"Diabetes"},{"key":"2116_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2215\/CJN.02960906","volume":"2","author":"P-CT Pham","year":"2007","unstructured":"P.-C.T. Pham, P.-M.T. Pham, S.V. Pham et al. Hypomagnesemia in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 2, 366\u2013373 (2007). \nhttps:\/\/doi.org\/10.2215\/CJN.02960906","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2116_CR3","doi-asserted-by":"publisher","unstructured":"J.C. Schutten, A.W. Gomes-Neto., G. Navis, et al. Lower plasma magnesium, measured by nuclear magnetic resonance spectroscopy, is associated with increased risk of developing type 2 diabetes mellitus in women: results from a Dutch prospective cohort study. J. Clin. Med. 8, 1\u201316 (2019). \nhttps:\/\/doi.org\/10.3390\/jcm8020169","DOI":"10.3390\/jcm8020169"},{"key":"2116_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.phrs.2016.06.019","volume":"111","author":"LE Simental-Mend\u00eda","year":"2016","unstructured":"L.E. Simental-Mend\u00eda, A. Sahebkar, M. Rodr\u00edguez-Mor\u00e1n, F. Guerrero-Romero, A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacol. Res. 111, 272\u2013282 (2016). \nhttps:\/\/doi.org\/10.1016\/j.phrs.2016.06.019","journal-title":"Pharmacol. Res."},{"key":"2116_CR5","first-page":"1024","volume":"21","author":"JL Nadler","year":"1993","unstructured":"J.L. Nadler, T. Buchanan, R. Natarajan et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertens. Dallas Tex. 1979 21, 1024\u20131029 (1993)","journal-title":"Hypertens. Dallas Tex. 1979"},{"key":"2116_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/ajcn\/55.6.1161","volume":"55","author":"G Paolisso","year":"1992","unstructured":"G. Paolisso, S. Sgambato, A. Gambardella et al. Daily magnesium supplements improve glucose handling in elderly subjects. Am. J. Clin. Nutr. 55, 1161\u20131167 (1992). \nhttps:\/\/doi.org\/10.1093\/ajcn\/55.6.1161","journal-title":"Am. J. Clin. Nutr."},{"key":"2116_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2337\/dc13-1397","volume":"37","author":"A Hruby","year":"2014","unstructured":"A. Hruby, J.B. Meigs, C.J. O\u2019Donnell et al. Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged americans. Diabetes Care 37, 419\u2013427 (2014). \nhttps:\/\/doi.org\/10.2337\/dc13-1397","journal-title":"Diabetes Care"},{"key":"2116_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/0895-4356(94)00200-A","volume":"48","author":"J Ma","year":"1995","unstructured":"J. Ma, A.R. Folsom, S.L. Melnick et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J. Clin. Epidemiol. 48, 927\u2013940 (1995)","journal-title":"J. Clin. Epidemiol."},{"key":"2116_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2337\/diacare.21.5.682","volume":"21","author":"M de Lordes Lima","year":"1998","unstructured":"M. de Lordes Lima, T. Cruz, J.C. Pousada et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 21, 682\u2013686 (1998)","journal-title":"Diabetes Care"},{"key":"2116_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2362.1982.tb00942.x","volume":"12","author":"P McNair","year":"1982","unstructured":"P. McNair, M.S. Christensen, C. Christiansen et al. Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. Eur. J. Clin. Investig. 12, 81\u201385 (1982)","journal-title":"Eur. J. Clin. Investig."},{"key":"2116_CR11","doi-asserted-by":"publisher","unstructured":"M.K. W\u00e4lti, M.B. Zimmermann, G.A. Spinas, R.F. Hurrell, Low plasma magnesium in type 2 diabetes. Swiss Med. Wkly 133, 289\u2013292 (2003). \nhttps:\/\/doi.org\/10.2003\/19\/smw-10170\n\n.","DOI":"10.2003\/19\/smw-10170"},{"key":"2116_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/00007611-199912000-00005","volume":"92","author":"N Mikhail","year":"1999","unstructured":"N. Mikhail, K. Ehsanipoor, Ionized serum magnesium in type 2 diabetes mellitus: its correlation with total serum magnesium and hemoglobin A1c levels. South Med. J. 92, 1162\u20131166 (1999)","journal-title":"South Med. J."},{"key":"2116_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-16-0517","volume":"176","author":"S Kurstjens","year":"2017","unstructured":"S. Kurstjens, J.H.F. de Baaij, H. Bouras et al. Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 176, 11\u201319 (2017). \nhttps:\/\/doi.org\/10.1530\/EJE-16-0517","journal-title":"Eur. J. Endocrinol."},{"key":"2116_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-22","volume":"14","author":"Y Roelofsen","year":"2014","unstructured":"Y. Roelofsen, S.H. Hendriks, F. Sieverink et al. Design of the e-Vita diabetes mellitus study: effects and use of an interactive online care platform in patients with type 2 diabetes (e-VitaDM-1\/ZODIAC-40). BMC Endocr. Disord. 14, 22 (2014). \nhttps:\/\/doi.org\/10.1186\/1472-6823-14-22","journal-title":"BMC Endocr. Disord."},{"key":"2116_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/13814788.2017.1292348","volume":"23","author":"SH Hendriks","year":"2017","unstructured":"S.H. Hendriks, E.G.W. van Soldt, M. van Vugt et al. Lifestyle and emotional well-being in men and women with type 2 diabetes (e-VitaDM-4; ZODIAC-48). Eur. J. Gen. Pract. 23, 83\u201390 (2017). \nhttps:\/\/doi.org\/10.1080\/13814788.2017.1292348","journal-title":"Eur. J. Gen. Pract."},{"key":"2116_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2012.10.001","volume":"104","author":"International Diabetes Federation Guideline Development Group","year":"2014","unstructured":"International Diabetes Federation Guideline Development Group, Global guideline for type 2 diabetes. Diabetes Res. Clin. Pract. 104, 1\u201352 (2014). \nhttps:\/\/doi.org\/10.1016\/j.diabres.2012.10.001","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2116_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"W.T. Friedewald, R.I. Levy, D.S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972)","journal-title":"Clin. Chem."},{"key":"2116_CR18","doi-asserted-by":"publisher","unstructured":"P.R. van Dijk, J.C. Schutten, E.J. Jeyarajah, et al. Blood Mg2+ is more closely associated with hyperglycaemia than with hypertriacylglycerolaemia: the PREVEND study. Diabetologia (2019). \nhttps:\/\/doi.org\/10.1007\/s00125-019-4929-7","DOI":"10.1007\/s00125-019-4929-7"},{"key":"2116_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0009-8981(79)90364-4","volume":"95","author":"HM Mather","year":"1979","unstructured":"H.M. Mather, J.A. Nisbet, G.H. Burton et al. Hypomagnesaemia in diabetes. Clin. Chim. Acta Int. J. Clin. Chem. 95, 235\u2013242 (1979). \nhttps:\/\/doi.org\/10.1016\/0009-8981(79)90364-4","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"2116_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.48","volume":"2","author":"H Saeed","year":"2019","unstructured":"H. Saeed, S. Haj, B. Qasim, Estimation of magnesium level in type 2 diabetes mellitus and its correlation with HbA1c level. Endocrinol. Diabetes Metab. 2, e00048 (2019). \nhttps:\/\/doi.org\/10.1002\/edm2.48","journal-title":"Endocrinol. Diabetes Metab."},{"key":"2116_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.4239\/wjd.v6.i10.1152","volume":"6","author":"M Barbagallo","year":"2015","unstructured":"M. Barbagallo, L.J. Dominguez, Magnesium and type 2 diabetes. World J. Diabetes 6, 1152\u20131157 (2015). \nhttps:\/\/doi.org\/10.4239\/wjd.v6.i10.1152","journal-title":"World J. Diabetes"},{"key":"2116_CR22","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1161\/ATVBAHA.117.309182","volume":"37","author":"AD Ter Braake","year":"2017","unstructured":"A.D. Ter Braake, C.M. Shanahan, J.H.F. de Baaij, Magnesium counteracts vascular calcification: passive interference or active modulation? Arterioscler Thromb. Vasc. Biol. 37, 1431\u20131445 (2017). \nhttps:\/\/doi.org\/10.1161\/ATVBAHA.117.309182","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"2116_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF00400855","volume":"35","author":"C Schnack","year":"1992","unstructured":"C. Schnack, I. Bauer, P. Pregant et al. Hypomagnesaemia in type 2 (non-insulin-dependent) diabetes mellitus is not corrected by improvement of long-term metabolic control. Diabetologia 35, 77\u201379 (1992)","journal-title":"Diabetologia"},{"key":"2116_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1681\/ASN.2010080888","volume":"22","author":"JP Ly","year":"2011","unstructured":"J.P. Ly, T. Onay, K. Sison et al. The Sweet Pee model for Sglt2 mutation. J. Am. Soc. Nephrol 22, 113\u2013123 (2011). \nhttps:\/\/doi.org\/10.1681\/ASN.2010080888","journal-title":"J. Am. Soc. Nephrol"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02116-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T23:29:33Z","timestamp":1603409373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02116-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2116"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02116-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was registered prior to the start of the study (study ID METC 11.10117) and approved by the Medical Ethical Committee of Isala (Zwolle, the Netherlands). The protocol was also registered on clinicaltrials.gov (study ID NCT01570140).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written and verbal informed consent was obtained from all subjects involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}